← Human Trials & Peer-Reviewed Studies
Endothelial progenitor cells in relation to endothelin-1 and endothelin receptor blockade: a randomized, controlled trial
Plain-language guide to PMID 23168014 (2013): double-blind randomized controlled trial study of Endothelin-1.
Key Facts
- PMID
- 23168014
- Journal
- International journal of cardiology
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Jung C et al. (4 authors)
- DOI
- 10.1016/j.ijcard.2012.10.032
What This Study Did, in Plain Language
What Was Tested
Researchers studied Endothelin-1 in this randomized controlled trial publication.
Endothelial progenitor cells (EPC) represent an endogenous repair mechanism involving rendothelialization and neoangiogenesis.
Patients with both diabetes and vascular disease have low numbers of circulating EPC.
Therefore, the researchers investigated the relation between EPC and plasma ET-1 and the effect of dual ET-1 receptor antagonist treatment.
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
Different EPC subpopulations were enumerated by flow cytometry using triple staining (CD34, CD133, KDR) at baseline at the end of treatment.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The participants were allocated by chance, so the Endothelin-1 group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Endothelin-1, so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Endothelin-1 could be set against what happens without it.
Viability was assessed by 7AAD and Annexin-V-staining.
What Was Measured
PubMed files the paper under topics including Albuminuria, Biomarkers, Bosentan, Diabetes Mellitus, Type 2, Endothelial Cells, Endothelin A Receptor Antagonists and Endothelin-1.
The authors tagged it with the keywords Endothelial progenitor cells and Vascular diseases.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Endothelin-1.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2013 (International journal of cardiology), a journal based in Netherlands.
More context: the Endothelin-1 compound page, all human trials.
Our Notes on the Compound
Endothelin-1: A 21-amino-acid peptide and one of the strongest blood-vessel constrictors in the body; given in research studies of vascular function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.